Pipeline targeting rare kidney and metabolic disease
1 On September 5, 2024, the FDA granted full approval of FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk for disease progression. Read the press release> CSL Vifor has exclusive commercial rights for sparsentan in Europe, Australia, and New Zealand. Read the press release> Renalys Pharma has exclusive commercial rights for sparsentan in Japan, South Korea, Taiwan, and Southeast Asian nations. Read the press release>
2 In December 2023, the Company announced that following its engagement with FDA on the two-year results from the DUPLEX Study, the Company is conducting additional analyses of FSGS data, and plans to re-engage with the FDA later in 2024 following the Company’s consideration of additional evidence. Read the press release>
3 In September 2024, Travere voluntarily paused the enrollment in the HARMONY Study due to commercial manufacturing scale-up. Read the press release>
FSGS: focal segmental glomerulosclerosis; IgAN: IgA nephropathy; HCU: classical homocystinuria